The Government of the US, as Represented by the Secretary, Department of Health and Human Services Patent applications |
Patent application number | Title | Published |
20120122123 | DETECTION OF ANTHRAX PATHOGENICITY FACTORS - One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, a patient may be days beyond the time when treatment would be effective by the time a diagnosis is made. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax lethal factor activity exhibited by the instant invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines and lethal factor inhibitors. The instant invention isolates and concentrates lethal factor and lethal toxin from nearly any biological sample. By capitalizing on the endopeptidase activity of lethal factor the present invention amplifies output signals producing reliable detection of picomolar concentrations of lethal factor. The instant invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax lethal factor in biological samples. | 05-17-2012 |
20120088244 | COMPOSITION AND METHODS FOR RAPID DETECTION OF HIV BY LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) - Methods and compositions for detection of HIV nucleic acids in a sample, such as a biological sample obtained from a human subject, are provided according to embodiments of the present invention which include providing a reaction mixture including at least one LAMP, accelerated LAMP, RT-LAMP or RT-accelerated LAMP assay primer set specific for HIV-I or HIV-2 nucleic acids and the biological sample to be tested for presence of HIV-I and/or HIV-2 nucleic acids; incubating the reaction mixture under conditions suitable to produce a LAMP assay reaction product; and detecting the reaction product. Primers and primer sets for use in LAMP assays of HIV-I or HIV-2 nucleic acids are provided. | 04-12-2012 |
20110268749 | TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-ALPHA2 - Disclosed herein are compositions and methods for treating or preventing cancer involving the use of a TNF-alpha antagonist, an IL-13Rα | 11-03-2011 |
20110201039 | IMPROVED VIRAL PROTEIN QUANTIFICATION PROCESS AND VACCINE QUALITY CONTROL THEREWITH - A process of quantifying proteins in a complex mixture is provided. The invention has utility in quantifying proteins in a complex preparation of uni- or multivalent commercial or research vaccine preparations. | 08-18-2011 |
20110171316 | EXPRESSION AND ASSEMBLY OF HUMAN GROUP C ROTAVIRUS-LIKE PARTICLES AND USES THEREOF - Group C rotaviruses are a cause of acute gastroenteritis in children and adults that is distinct from group A RV. However, human group C rotaviruses cannot be grown in culture, resulting in a lack of tools for detection and treatment of GrpC RV disease. Consequently, the burden of GpC RV disease has not been clearly established. Isolated recombinant human rotavirus group C virus-like particles are provided according to embodiments of the present invention along with methods of their production and use in, inter alia, detection of Grp C RV infection, diagnostic assays and immunogenic compositions. | 07-14-2011 |
20110086416 | IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF - The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. | 04-14-2011 |
20100099201 | METHODS AND COMPOSITIONS RELATING TO ISOCYANATE CONJUGATES - Compositions are provided according to embodiments of the present invention which include an isolated antibody or antigen binding antibody fragment characterized by binding specificity for a conjugate which is a reaction product of a protein moiety and an isocyanate moiety. Methods of detecting diisocyanate-protein conjugates in a sample are provided according to embodiments of the present invention which include contacting a sample with one or more isolated antibodies or antigen binding antibody fragments characterized by binding specificity for corresponding diisocyanate-protein conjugate antigens. | 04-22-2010 |